3 completed, 2 recruiting, 2 unknown, 1 terminated. 5 Phase 2, 3 Phase 1, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Not applicable | 2 | Unknown 2 |
Follow Clenbuterol: new trials by email Literature Review of Clenbuterol trials Research Report on Clenbuterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clenbuterol to Target DUX4 in FSHD Clenbuterol - Muscular Dystrophy, Facioscapulohumeral | Phase 1 | Recruiting | Jeffrey Statland | 30 | 2025-06-25 | 2026-02-25 |
| A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy Clenbuterol, Placebo - Spinal and Bulbar Muscular Atrophy | Phase 2 | Recruiting | Gianni Soraru | 90 | 2024-04-13 | 2024-04-15 |
| Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans Clenbuterol, Placebo - Skeletal Muscle Physiology | Not applicable | Unknown | Morten Hostrup, PhD | 60 | 2023-02-01 | 2023-01-20 |
| Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease Clenbuterol, Placebos - Pompe Disease (Late-onset) | Phase 2 | Withdrawn | Duke University | 2023-01-01 | 2022-08-17 | |
| A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders clenbuterol (CST-103), nadolol (CST-107), matching placebo - Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia | Phase 2 | Completed | CuraSen Therapeutics, Inc. | 41 | 2021-06-28 | 2024-12-02 |
| Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis Clenbuterol - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Dwight Koeberl, M.D., Ph.D. | 25 | 2020-02-10 | 2022-09-06 |
| cAMP Signaling and Muscle Adaptations No training, Endurance training, Resistance Training - Muscle Hypertrophy in Healthy Young Men | Not applicable | Unknown | University of Copenhagen | 72 | 2015-07-01 | 2017-10-26 |
| Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy Clenbuterol, Placebo - Pompe Disease | Phase 1 / Phase 2 | Completed | Dwight Koeberl, M.D., Ph.D. | 17 | 2013-09-01 | 2019-07-02 |
| Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure clenbuterol - Heart Failure, Dilated Cardiomyopathy | Phase 1 | Terminated | Francis D. Pagani | 18 | 2007-07-01 | 2017-12-15 |
Glycogen Storage Disease Type II (2) · Amyotrophic Lateral Sclerosis (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Cardiomyopathy, Dilated (1) · Cognitive Dysfunction (1) · Heart Failure (1) · Lewy Body Disease (1) · Muscular Dystrophy, Facioscapulohumeral (1)
Dwight Koeberl, M.D., Ph.D. (2) · CuraSen Therapeutics, Inc. (1) · Duke University (1) · Francis D. Pagani (1) · Gianni Soraru (1) · Jeffrey Statland (1) · Morten Hostrup, PhD (1) · University of Copenhagen (1)
United States (5) · Denmark (2) · Australia (1) · Italy (1) · New Zealand (1) · United Kingdom (1)
Dwight D Koeberl, MD, PhD (1) · Dwight Koeberl, MD, PhD (1) · Francis D. Pagani, MD, PhD (1) · Keith D. Aaronson, MD, MS (1) · Leslie W. Miller, MD (1)
P50AR065139 (1)